Physician profile
James A Smith
NPI 1033150222
$657.75
in general payments reported to CMS, 2019-2025
14 companies · $17.43 in 2025
The $17.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $95.57 · 2021: $142 · 2022: $77.52 · 2023: $72.50 · 2024: $125 · 2025: $17.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $215.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $165.05 | 2019-2021 | |
| Irras USA, INC. | $125.17 | 2024 | |
| Abbott Laboratories | $87.63 | 2019-2025 | |
| Abbvie INC. | $53.96 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $46.48 | 2023 | |
| Pfizer INC. | $37.83 | 2019-2021 | |
| Insmed, INC. | $33.59 | 2021 | |
| Glaxosmithkline, LLC. | $20.96 | 2022 | |
| Astellas Pharma US INC | $18.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.20 | 2021 | |
| Amgen INC. | $14.62 | 2023 | Repatha, Otezla |
| Allergan, INC. | $12.79 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.